NASDAQ:CNTX Context Therapeutics (CNTX) Stock Price, News & Analysis $0.37 -0.02 (-3.99%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$0.38 +0.01 (+2.15%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Context Therapeutics Stock (NASDAQ:CNTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Context Therapeutics alerts:Sign Up Key Stats Today's Range$0.37▼$0.4050-Day Range$0.35▼$0.6952-Week Range$0.34▼$3.62Volume1.12 million shsAverage Volume1.71 million shsMarket Capitalization$33.82 millionP/E RatioN/ADividend YieldN/APrice Target$6.17Consensus RatingModerate Buy Company Overview Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immune-based treatments for solid tumors, with an emphasis on cancers that have limited treatment options. The company is headquartered in Philadelphia and conducts development activities through collaborations and clinical research networks. Its lead investigational program is CTIM-76, a bispecific antibody designed to recognize Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. By bringing T cells into proximity with CLDN6-expressing cancer cells, the treatment is intended to stimulate an immune response against tumors. CTIM-76 is being evaluated in early-stage clinical research for patients with advanced solid tumors. Context Therapeutics was founded in 2015 and became a publicly traded company in 2021. The company previously pursued therapies for hormone-responsive cancers, including the progesterone-receptor antagonist onapristone, before shifting its primary focus toward CLDN6-directed cancer immunotherapies. Context Therapeutics is led by Chief Executive Officer Martin Lehr.AI Generated. May Contain Errors. Read More Context Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreCNTX MarketRank™: Context Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 520th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingContext Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialContext Therapeutics has a consensus price target of $6.17, representing about 1,575.3% upside from its current price of $0.37.Amount of Analyst CoverageContext Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Context Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Context Therapeutics are expected to grow in the coming year, from ($0.45) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Context Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Context Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContext Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Context Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.39% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Context Therapeutics has recently increased by 3.09%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldContext Therapeutics does not currently pay a dividend.Dividend GrowthContext Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Context Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for CNTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Context Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.80% of the stock of Context Therapeutics is held by insiders.Percentage Held by Institutions14.03% of the stock of Context Therapeutics is held by institutions.Read more about Context Therapeutics' insider trading history. Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTX Stock News HeadlinesContext Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 19 at 4:29 AM | americanbankingnews.comContext Doses First Patient In Phase 1 For Cancer Drug CT-202September 9, 2026 | rttnews.comTrump's new AI tirade hurting GOP?President Trump says AI will become the greatest economic development engine in history, dismissing fears of disruption. Meanwhile, the GOP is working to ease AI concerns ahead of the midterm elections. Investor Whitney Tilson sees this growing divide as the start of an 'AI Civil War,' set to unfold in less than 100 days with major implications for markets.September 20 at 1:00 AM | Stansberry Research (Ad)Context Doses First Patient In Phase 1 For Cancer Drug CT-202September 9, 2026 | rttnews.comContext Therapeutics Doses First Patient in Phase 1 Trial of CT-202 for Solid TumorsSeptember 9, 2026 | quiverquant.comQContext Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202September 9, 2026 | globenewswire.comLifeSci Capital downgrades Context Therapeutics (CNTX) to a HoldAugust 10, 2026 | theglobeandmail.comContext Therapeutics stock (CNTX) is falling after hours: Here's what's driving the moveAugust 6, 2026 | msn.comSee More Headlines CNTX Stock Analysis - Frequently Asked Questions How have CNTX shares performed this year? Context Therapeutics' stock was trading at $1.47 at the start of the year. Since then, CNTX stock has decreased by 75.0% and is now trading at $0.3681. How were Context Therapeutics' earnings last quarter? Context Therapeutics Inc. (NASDAQ:CNTX) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.06. When did Context Therapeutics IPO? Context Therapeutics (CNTX) raised $25 million in an initial public offering (IPO) on Tuesday, October 19th 2021. The company issued 5,000,000 shares at a price of $5.00 per share. Who are Context Therapeutics' major shareholders? Context Therapeutics' top institutional shareholders include BlackRock Inc. (6.71%), Blue Owl Capital Holdings LP (3.19%), ADAR1 Capital Management LLC (0.82%) and Timothy G. Youngquist 2020 Irrevocable Trust (0.22%). Insiders that own company stock include Martin A Lehr, Jennifer Lynn Minai-Azary and Alex C Levit. View institutional ownership trends. How do I buy shares of Context Therapeutics? Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Context Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Context Therapeutics investors own include NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Celestica (CLS). Company Calendar Last Earnings8/05/2026Today9/20/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CNTX's financial health is in the Red zone, according to TradeSmith. CNTX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CNTX CIK1842952 Webwww.contexttherapeutics.com Phone267-225-7416FaxN/AEmployees15Year Founded2015Price Target and Rating Average Price Target for Context Therapeutics$6.17 High Price Target$9.00 Low Price Target$4.00 Potential Upside/Downside+1,575.3%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-82.06% Return on Assets-72.74% Debt Debt-to-Equity RatioN/A Current Ratio5.81 Quick Ratio5.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book0.56Miscellaneous Outstanding Shares91,880,000Free Float87,469,000Market Cap$33.82 million OptionableNot Optionable Beta1.69 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:CNTX) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...Golden Portfolio | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
